News releases - Merck.com
WEB5 days ago · August 29, 2024. Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials. August 27, 2024. Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia. August 26, 2024.
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
WEB2 days ago · Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...
Merck's Keytruda Secures First FDA-Approval For Rare Form …
WEB3 days ago · Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...
Merck wins first FDA approval for Keytruda as a treatment for ...
WEB4 days ago · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
What can we help you find? - Merck
WEB2 days ago · This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject ...
News & Stories - Merck
WEBSep 12, 2024 · Check out the latest Merck news and stories! Learn more about the leading science and technology company here.
New MAVENCLAD 4-year data highlighting sustained efficacy - Merck
WEBSep 12, 2024 · Merck Unveils New MAVENCLAD. ®. Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity. Merck today announced presentations showcasing the long-term safety profile, sustained efficacy data, and durable effect of MAVENCLAD® (cladribine) tablets in …
Merck Gets European Panel Backing for Keytruda in Two …
WEB2 days ago · Merck added that the European Commission, which generally follows the CHMP's advice, is expected to make final decisions by the end of the year. ... Dow Jones Newswires is a market-moving ...
Merck Keytruda approved by FDA for mesothelioma (NYSE:MRK)
WEB4 days ago · Merck (NYSE: MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination ...
Merck Enters Two Strategic Collaborations to Strengthen AI …
WEBSep 20, 2023 · Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.